Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation

Europace

Volumn 16, Issue 8, 2014, Pages 1137-1144

  Providência, Rui ^a,b   Marijon, Eloi ^c   Albenque, Jean Paul ^a   Combes, Stéphane ^a   Combes, Nicolas ^a   Jourda, François ^a   Hireche, Hassiba ^a   Morais, João ^d   Boveda, Serge ^a  

^a CLINIQUE PASTEUR   (France)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^d Hospital de Santo Andre   (Portugal)

Author keywords

Arrhythmia; Atrial fibrillation; Bleeding; Cryoablation; Dabigatran; Fluindione; Rivaroxaban; Stroke; Thromboembolism; Vitamin K antagonists

Indexed keywords

ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DABIGATRAN; MORPHOLINE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE;

ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; BLEEDING; CATHETER ABLATION; CHEMICALLY INDUCED; CLINICAL PRACTICE; DRUG UTILIZATION REVIEW; FEMALE; HUMAN; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PORTUGAL; PRESCRIPTION; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; TIME FACTOR; TREATMENT OUTCOME; TRENDS;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CATHETER ABLATION; DABIGATRAN; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PORTUGAL; PRACTICE PATTERNS, PHYSICIANS'; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; RIVAROXABAN; THIOPHENES; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME;

EID: 84905576575     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euu007     Document Type: Article

References (23)

1. WilkeT, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace 2013;15:486-93.
2. Crawford T, Oral H. Current status and outcomes of catheter ablation for atrial fibrillation. Heart Rhythm 2009;6(12 Suppl):S12-7.
3. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA et al. 2012 HRS/ EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012;14:528-606.
4. Hussein AA, Martin DO, Saliba W, Patel D, Karim S, Batal O et al. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm 2009;6: 1425-9.
5. Providencia R, Albenque JP, Combes S, Bouzeman A, Casteigt B, Combes N et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart 2014; 100:324-35.
6. Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace 2013;15: 1407-11.
7. Sorgente A, Chierchia GB, de Asmundis C, Sarkozy A, Capulzini L, Brugada P. Complications of atrial fibrillation ablation: when prevention is better than cure. Europace 2011;13:1526-32.
8. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, Pruszczyk P et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis andManagement of Acute PulmonaryEmbolism of the European Society of Cardiology (ESC). Eur Heart J 2008;29:2276-315.
9. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4.
10. Eitel C, Koch J, Sommer P, John S, Kircher S, Bollmann A et al. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace 2013;15:1587-93.
11. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, SingerDE et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 2013;61:1998-2006.
12. A study exploring two treatment strategies in patients with atrial fibrillation who undergo catheter ablation therapy (VENTURE-AF). http://clinicaltrials.gov/show/ NCT01729871.
13. Deshmukh A, Patel NJ, Pant S, Shah N, Chothani A, Mehta K et al. Inhospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000-2010: analysis of 93,801 procedures. Circulation 2013;128:2104-12.
14. Bin Abdulhak AA, Khan AR, Tleyjeh IM, Spertus JA, Sanders SU, Steigerwalt KE et al. Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Europace 2013;15:1412-20.
15. Ghia KK, Chugh A, Good E, Pelosi F, Jongnarangsin K, Bogun F et al. A nationwide survey on the prevalence of atrio-esophageal fistula after left atrial radiofrequency catheter ablation. J Interv Card Electrophysiol 2009;24:33-6.
16. Ootani A, Hayashi Y, Miyagi Y. Dabigatran-induced esophagitis. Clin Gastroenterol Hepatol 2013. pii: S1542-3565(13)01307-4. (EPUB ahead of print).
17. Kim JS, She F, Jongnarangsin K, Chugh A, Latchamsetty R, GhanbariHet al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 2013;10:483-9.
18. MaddoxW, Kay GN, Yamada T, Osorio J, Doppalapudi H, Plumb VJ et al. Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. J Cardiovasc Electrophysiol 2013;24:861-5.
19. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413.
20. Raviele A, Natale A, Calkins H, CammJA, Cappato R, Ann Chen S et al. Venice Chart International Consensus Document on atrial fibrillation ablation: 2011 update. J Cardiovasc Electrophysiol 2012;23:890-923.
21. Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Caro J, Drouet L. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the International Study of Anticoagulation Management (ISAM). J Thromb Thrombolysis 2007;23: 83-91.
22. Fihn SD, Gadisseur AA, Pasterkamp E, van der Meer FJ, Breukink-Engbers WG, Geven-Boere LM et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost 2003;90: 260-6.
23. Santangeli P, Di Biase L, Horton R, Burkhardt JD, Sanchez J, Al-Ahmad A et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis. Circ Arrhythm Electrophysiol 2012;5: 302-11.